# Tempest Therapeutics, Inc.: financial statements, quarterly

TPST · Nasdaq · CIK 1544227 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tpst.md) · [Financials](/companies/tpst/financials.md) · [Filings](/companies/tpst/filings.md) · [Insiders](/companies/tpst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tpst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(6.6)](/filings/0000950170-24-125499.md) | [(7.5) d](/filings/0000950170-25-046144.md) | [(8.0)](/filings/0000950170-25-070441.md) | [(9.6)](/filings/0000950170-25-106558.md) | [(10.6)](/filings/0001193125-25-265946.md) | [(13.9) d](/filings/0001193125-26-130490.md) | [(10.9)](/filings/0001193125-26-224289.md) | [(8.0)](/filings/0001193125-26-349381.md) | [(3.6)](/filings/0001193125-25-265946.md) | [(4.1) d](/filings/0001193125-26-130490.md) | [(27.7)](/filings/0001193125-26-224289.md) | [(5.3)](/filings/0001193125-26-349381.md) |
| Interest expense | $m | [0.4](/filings/0000950170-23-061278.md) | [0.4 d](/filings/0000950170-24-033555.md) | [0.4](/filings/0000950170-24-057072.md) | [0.4](/filings/0000950170-24-094124.md) | [0.3](/filings/0001193125-25-265946.md) | [0.2 d](/filings/0001193125-26-130490.md) | [0.2](/filings/0001193125-26-224289.md) | [0.0](/filings/0001193125-26-349381.md) | [0.0](/filings/0001193125-25-265946.md) | [0.0 d](/filings/0001193125-26-130490.md) | [0.0](/filings/0001193125-26-224289.md) | [0.0](/filings/0001193125-26-349381.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-125499.md) | [0.0 d](/filings/0000950170-25-046144.md) | [0.0](/filings/0000950170-25-070441.md) | [0.0](/filings/0000950170-25-106558.md) | [0.0](/filings/0001193125-25-265946.md) | [0.0 d](/filings/0001193125-26-130490.md) | [0.0](/filings/0001193125-26-224289.md) | [0.0](/filings/0001193125-26-349381.md) | [0.0](/filings/0001193125-25-265946.md) | [0.0 d](/filings/0001193125-26-130490.md) | [0.0](/filings/0001193125-26-224289.md) | [0.0](/filings/0001193125-26-349381.md) |
| Net income | $m | [(6.8)](/filings/0000950170-24-125499.md) | [(7.5) d](/filings/0000950170-25-046144.md) | [(7.9)](/filings/0001193125-25-265946.md) | [(9.6)](/filings/0001193125-25-265946.md) | [(10.6)](/filings/0001193125-25-265946.md) | [(13.8) d](/filings/0001193125-26-130490.md) | [(10.9)](/filings/0001193125-26-349381.md) | [(7.9)](/filings/0001193125-26-349381.md) | [(3.5)](/filings/0001193125-25-265946.md) | [(4.0) d](/filings/0001193125-26-130490.md) | [(27.7)](/filings/0001193125-26-349381.md) | [(5.2)](/filings/0001193125-26-349381.md) |
| Diluted EPS | $ per share | [(0.48)](/filings/0000950170-24-125499.md) | not reported | [(4.62)](/filings/0000950170-25-070441.md) | [(5.52)](/filings/0000950170-25-106558.md) | [(5.32)](/filings/0001193125-25-265946.md) | not reported | [(3.16)](/filings/0001193125-26-224289.md) | [(2.07)](/filings/0001193125-26-349381.md) | [(0.79)](/filings/0001193125-25-265946.md) | not reported | [(2.53)](/filings/0001193125-26-224289.md) | [(0.34)](/filings/0001193125-26-349381.md) |
| Basic EPS | $ per share | [(0.48)](/filings/0000950170-24-125499.md) | not reported | [(4.62)](/filings/0000950170-25-070441.md) | [(5.52)](/filings/0000950170-25-106558.md) | [(5.32)](/filings/0001193125-25-265946.md) | not reported | [(3.16)](/filings/0001193125-26-224289.md) | [(2.07)](/filings/0001193125-26-349381.md) | [(0.79)](/filings/0001193125-25-265946.md) | not reported | [(2.53)](/filings/0001193125-26-224289.md) | [(0.34)](/filings/0001193125-26-349381.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Research and development: not reported
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.1](/filings/0000950170-23-061278.md) | [39.2](/filings/0000950170-25-046144.md) | [32.3](/filings/0000950170-24-057072.md) | [31.1](/filings/0000950170-24-094124.md) | [22.1](/filings/0000950170-24-125499.md) | [30.3](/filings/0001193125-26-130490.md) | [21.5](/filings/0000950170-25-070441.md) | [14.3](/filings/0000950170-25-106558.md) | [7.5](/filings/0001193125-25-265946.md) | [7.7](/filings/0001193125-26-349381.md) | [1.8](/filings/0001193125-26-224289.md) | [0.8](/filings/0001193125-26-349381.md) |
| Current assets | $m | [12.3](/filings/0000950170-23-061278.md) | [40.4](/filings/0000950170-25-046144.md) | [33.5](/filings/0000950170-24-057072.md) | [31.5](/filings/0000950170-24-094124.md) | [23.6](/filings/0000950170-24-125499.md) | [31.5](/filings/0001193125-26-130490.md) | [22.4](/filings/0000950170-25-070441.md) | [15.1](/filings/0000950170-25-106558.md) | [8.1](/filings/0001193125-25-265946.md) | [8.3](/filings/0001193125-26-349381.md) | [2.4](/filings/0001193125-26-224289.md) | [1.7](/filings/0001193125-26-349381.md) |
| Total assets | $m | [24.0](/filings/0000950170-23-061278.md) | [51.6](/filings/0000950170-25-046144.md) | [44.4](/filings/0000950170-24-057072.md) | [42.2](/filings/0000950170-24-094124.md) | [33.8](/filings/0000950170-24-125499.md) | [41.5](/filings/0001193125-26-130490.md) | [32.2](/filings/0000950170-25-070441.md) | [24.5](/filings/0000950170-25-106558.md) | [17.1](/filings/0001193125-25-265946.md) | [16.9](/filings/0001193125-26-349381.md) | [10.7](/filings/0001193125-26-224289.md) | [9.6](/filings/0001193125-26-349381.md) |
| Current liabilities | $m | [7.4](/filings/0000950170-23-061278.md) | [9.4](/filings/0000950170-25-046144.md) | [10.7](/filings/0000950170-24-057072.md) | [14.6](/filings/0000950170-24-094124.md) | [14.0](/filings/0000950170-24-125499.md) | [14.2](/filings/0001193125-26-130490.md) | [13.2](/filings/0000950170-25-070441.md) | [7.1](/filings/0000950170-25-106558.md) | [3.5](/filings/0001193125-25-265946.md) | [3.3](/filings/0001193125-26-349381.md) | [3.3](/filings/0001193125-26-224289.md) | [4.5](/filings/0001193125-26-349381.md) |
| Total liabilities | $m | [25.2](/filings/0000950170-23-061278.md) | [24.8](/filings/0000950170-25-046144.md) | [23.7](/filings/0000950170-24-057072.md) | [25.2](/filings/0000950170-24-094124.md) | [22.4](/filings/0000950170-24-125499.md) | [22.4](/filings/0001193125-26-130490.md) | [21.0](/filings/0000950170-25-070441.md) | [14.7](/filings/0000950170-25-106558.md) | [10.8](/filings/0001193125-25-265946.md) | [10.3](/filings/0001193125-26-349381.md) | [9.9](/filings/0001193125-26-224289.md) | [10.7](/filings/0001193125-26-349381.md) |
| Long-term debt | $m | [8.4](/filings/0000950170-23-061278.md) | [6.3](/filings/0000950170-25-046144.md) | [4.1](/filings/0000950170-24-057072.md) | [2.0](/filings/0000950170-24-094124.md) | [0.0](/filings/0000950170-24-125499.md) | [0.0](/filings/0000950170-25-046144.md) | [4.2](/filings/0000950170-25-070441.md) | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [2.1](/filings/0000950170-23-061278.md) | [4.3](/filings/0000950170-25-046144.md) | [6.5](/filings/0000950170-24-057072.md) | [8.6](/filings/0000950170-24-094124.md) | [8.5](/filings/0000950170-24-125499.md) | [6.4](/filings/0001193125-26-130490.md) | [4.2](/filings/0000950170-25-070441.md) | [0.0](/filings/0000950170-25-106558.md) | [0.0](/filings/0001193125-25-265946.md) | [0.0](/filings/0001193125-26-130490.md) | not reported | not reported |
| Shareholders' equity | $m | [(1.2)](/filings/0000950170-24-125499.md) | [26.8](/filings/0001193125-26-130490.md) | [20.6](/filings/0001193125-25-265946.md) | [16.9](/filings/0001193125-25-265946.md) | [11.5](/filings/0001193125-25-265946.md) | [19.1](/filings/0001193125-26-349381.md) | [11.1](/filings/0001193125-26-349381.md) | [9.8](/filings/0001193125-26-349381.md) | [6.3](/filings/0001193125-25-265946.md) | [6.7](/filings/0001193125-26-349381.md) | [0.8](/filings/0001193125-26-349381.md) | [(1.1)](/filings/0001193125-26-349381.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.5) d](/filings/0000950170-24-125499.md) | [(6.2) d](/filings/0000950170-25-046144.md) | [(7.2)](/filings/0000950170-25-070441.md) | [(5.5) d](/filings/0000950170-25-106558.md) | [(10.2) d](/filings/0001193125-25-265946.md) | [(10.1) d](/filings/0001193125-26-130490.md) | [(8.0)](/filings/0001193125-26-224289.md) | [(8.4) d](/filings/0001193125-26-349381.md) | [(6.8) d](/filings/0001193125-25-265946.md) | [(3.6) d](/filings/0001193125-26-130490.md) | [(7.6)](/filings/0001193125-26-224289.md) | [(2.8) d](/filings/0001193125-26-349381.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125499.md) | [0.0 d](/filings/0000950170-25-046144.md) | [0.2](/filings/0000950170-25-070441.md) | [0.2 d](/filings/0000950170-25-106558.md) | [0.0 d](/filings/0001193125-25-265946.md) | [0.0 d](/filings/0001193125-26-130490.md) | [0.0](/filings/0001193125-26-224289.md) | [0.0 d](/filings/0001193125-26-349381.md) | [0.0 d](/filings/0001193125-25-265946.md) | [0.0 d](/filings/0001193125-26-130490.md) | [0.0](/filings/0001193125-26-224289.md) | [0.0 d](/filings/0001193125-26-349381.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.6](/filings/0000950170-23-061278.md) | [13.8](/filings/0000950170-24-057072.md) | [14.1](/filings/0000950170-24-094124.md) | [14.1](/filings/0000950170-24-125499.md) | [1.7](/filings/0000950170-25-070441.md) | [1.7](/filings/0000950170-25-106558.md) | [2.0](/filings/0001193125-25-265946.md) | [3.4](/filings/0001193125-26-224289.md) | [3.8](/filings/0001193125-26-349381.md) | [4.4](/filings/0001193125-25-265946.md) | [10.9](/filings/0001193125-26-224289.md) | [15.2](/filings/0001193125-26-349381.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,806,997 at 2026-05-08, from the cover of the [10-Q filed 2026-05-14](/filings/0001193125-26-224289.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.